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Abstract. The purpose of this article is to catalogue in a systematic way the available information about
factors that may influence the outcome and variability of cascade impactor (CI) measurements of
pharmaceutical aerosols for inhalation, such as those obtained from metered dose inhalers (MDIs), dry
powder inhalers (DPIs) or products for nebulization; and to suggest ways to minimize the influence of
such factors. To accomplish this task, the authors constructed a cause-and-effect Ishikawa diagram for a
CI measurement and considered the influence of each root cause based on industry experience and
thorough literature review. The results illustrate the intricate network of underlying causes of CI
variability, with the potential for several multi-way statistical interactions. It was also found that
significantly more quantitative information exists about impactor-related causes than about operator-
derived influences, the contribution of drug assay methodology and product-related causes, suggesting a
need for further research in those areas. The understanding and awareness of all these factors should aid
in the development of optimized CI methods and appropriate quality control measures for aerodynamic
particle size distribution (APSD) of pharmaceutical aerosols, in line with the current regulatory initiatives
involving quality-by-design (QbD).
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INTRODUCTION
Quality control systems, generally speaking, are intended
(a) to monitor (i.e., measure) selected parameters of a product,
which are deemed critical quality attributes, (b) to compare
outcomes of these measurements with pre-determined sets of
criteria deemed to describe “typical”, “in-control” situations,
and (c) toalertthemanufacturer ifany ofthemonitored metrics
are approaching or exceeding their allowed ranges. In order to
fulfill these requirements, an appropriate quality control system
must have at its disposal such tools and metrics that would allow
themanufacturertoextractinformationabouttheproductitself,
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method. Unfortunately, one of the core measurements of an
important quality parameter for orally inhaled and nasal drug
products, namely a cascade impactor measurement of aerody-
namic particle size distribution (APSD), while providing
information not always available from other particle-sizing
methods (1–6) has long been recognized in the scientific
community as being problematic because many factors not
related to product quality may influence the CI measurement
outcome (2,7–8). This report aims to catalogue in a systematic
way all pertinent information about factors potentially influenc-
ing a CImeasurementoutcomeandtosuggestways tominimize
CImethod-relateduncertaintiesandoptimizetheCImethodfor
a givenapplication. This reviewwillbe ofparticularhelpwhen a
company is developing a CI method in a systematic way,
identifying various sources of variability as well as ways to
eliminate, minimize and/or control them. Furthermore, this
paper could serve as an aid in identifying root-causes of
“deviating” CI results during laboratory investigations, either
as part of method development or in routine quality control.
More generally, the current consolidated review of
factors influencing CI measurements could serve as a step
towards development of improved approaches of controlling
APSD in inhaled products and should help individual sponsor
discussions with regulators under the current QbD paradigm
(9–13).
The other aspect of the QbD approach as it relates to CI
and APSD measurements, namely establishing links between
quality controls and clinical outcomes, has been discussed
elsewhere (14) and is outside the scope of this review.
METHODS
A working group of the International Pharmaceutical
Aerosol Consortium on Regulation and Science (IPAC-RS)
was formed in 2005 to explore the issue of CI method
variability. The group included experts in product develop-
ment, manufacturing, quality control and regulatory affairs.
Based on the members’ experience and thorough literature
review, the group constructed an Ishikawa Diagram (Fig. 1)
that visualized and categorized the factors that may affect a
CI measurement. As is typical for Ishikawa Diagrams, the
following major categories of factors were included: “man”
(i.e., CI operator/analyst), “machine” (i.e., the CI, its
accessories and operating/environmental conditions), “mea-
Fig. 1. An Ishikawa Diagram summarizing factors influencing the uncertainty of a CI measurement (both its bias, or systematic error, and
variability, or random error)
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ceutical ingredient (API), such as HPLC analysis], and
“material” (i.e., medicinal formulation together with its
delivery device). Focused literature searches and internal
company surveys were then undertaken to assemble available
evidence in each category and to provide specific recommen-
dations for minimizing influence of the identified factors.
RESULTS AND DISCUSSION
Man (CI Operator/Analyst)
Performing a CI measurement requires several manual
operations, such as impactor assembly, connections to vacu-
um valves and pump, adjustment of air flowrate, inhaler
manipulation and actuation, quantitative recovery of the
deposited API, dilution for subsequent HPLC–spectrophoto-
metric assay of API or other type of analysis. Human
involvement in these steps, both due to imperfect technique
and as a result of unintentional mistakes, increases the
likelihood of bias and increased variability unless adequate
measures are included in the method (7). Fully automated
impactors have been developed to reduce operator-related
error (15,16), however they are expensive (>$ 1M), complex,
and resource-intensive to develop and validate because a
separate method is needed for each individual product. The
future may, therefore, be with a lower-cost semi-automated
approach, such as the “Service-Head” technology proposed
by Miller et al. (17) in which operator involvement is reduced.
As a means of controlling automation costs with the Next
Generation Pharmaceutical Impactor (NGI), they proposed
simplifying the liquid handling procedures involved in API
recovery by making liquid streams required for API dissolu-
tion the primary motion of the process, and minimizing the
physical motion of the impactor components. Other aids that
speed up the process of impactor measurements in a semi-
automated way can be an effective and low-cost solution for
most users (so-called aided technology). Equipment that
enables stage coatings to be applied in a reproducible manner
or assists in the reproducible recovery of API from individual
stages, are examples of this relatively simple approach to the
problem of reducing operator-related error. Initial findings
with one such system indicated both excellent API recovery
(ca. 99% of label claim), together with greatly reduced cycle
times compared with manual Andersen Cascade Impactor
(ACI) (18). Other steps in the direction of increased
throughput and reduced human involvement include use of
single-stage impactors or liquid impingers (19–21). In addi-
tion, an older twin-impinger apparatus is still an effective
device for rapid screening studies although it does not
provide high size resolution (22). Despite these alternatives
and recent developments, the conventional eight-stage ACI
(apparatus 1 in the US Pharmacopeia Chapter <601>, 23) and
other manual systems based on highly laborious methods are
likely to remain in use by most organizations for the
foreseeable future especially for regulatory purposes (24).
People-related variability can, therefore, be expected to
continue to be a significant contributing factor to the overall
CI test outcomes. A further detailed discussion of some of the
man-related factors is presented below.
Impactor Assembly
Operator training in impactor assembly is crucial, in
particular with stack designs such as the ACI, due to the need
to assure correct stage order (7) as well as ensuring that there
is a proper seal between impactor stages. A gantry type
system could be used to ensure the stack is properly aligned.
Proper sealing could be checked via leak tests and/or
pressure-drop tests, or by including a differential mass flow-
meter at the throat and the impactor exit. A checklist may be
a helpful aid, particularly for an inexperienced operator (7).
However, even with proper training, occasional errors in the
assembly of ACI-type impactors are likely, given the com-
plexity of the process, leading to “failed” CI tests. For
example, incorrect ordering (switching) of CI stages or
misalignment of collection plates in an ACI are inadvertent
errors that may happen even to a well-trained operator (7). A
complete set of cups can be fixed permanently into a carrier
that makes the process of loading and unloading the impactor
more efficient. For an NGI, the stage order is fixed due to the
integral nature of the impactor body (25).
Inhaler Handling and Sample Introduction
Proper training in sample collection is critical because of
a wide variety of different test methods, including variations
in inhaler handling and introduction of the sample to the CI
(26). Even with proper training, individual differences
between operators (e.g., inhaler shaking frequency and
intensity, delay between shaking and actuation, alignment of
inhaler to ACI, actuation) may go unnoticed but may result in
different systematic biases (e.g., dose-through-use trends) and
also may contribute to the seemingly random variability when
results are compared from several operators or even from the
same operator on different occasions. For example, a
different rate of actuating an MDI may lead to different
cooling of the canister (27) and, therefore, different evapora-
tion behavior of the propellant, leading to variations in
measured APSD, even when the inhaler units are identical.
Using a bench timer may help standardize this aspect of the
method and minimize the associated variability; automation
of some of these steps may further reduce this type of
variability (27).
HPLC Standard Preparation
When HPLC is used for API assay, an analyst might
introduce an “individual” bias into APSD results by prepar-
ing the HPLC standard at the upper or lower limit of the pre-
defined range, so that all recoveries from the CI stages would
either be slightly over- or under-estimated.
CI Sample Collection and HPLC Analysis
The procedure for API recovery from the CI and
subsequent analysis offers multiple opportunities for errors
including loss of deposited API on disassembly of the
impactor prior to API recovery. Therefore, careful handling
of the stack and API-coated plates as well as a robust
technique for recovering API material deposited on CI
surfaces are critical, as is proper organization of samples to
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Pipetting contributes to random variations (more careful
pipetting leading to a complete discharge, less careful leading
to some drops left over in the pipette), therefore, automated
pipettes should be considered. Another potential source of
variability is due to the use of different volumes for stage
dissolution or for dilution of recovered samples, e.g., in order
to obtain the same concentration for all API stage-by-stage
samples to be quantified using LC analysis. Potential errors
and increased variability should be weighed against potential
benefits of this procedure.
Evaporation of solvent during sample recovery will give
an overestimation of the API amount and its effects should be
minimized, e.g., by inclusion of an internal chemical standard
in the solvent used for recovery. If the HPLC method has
good linearity, it is also possible to dispense the same volume
of internal standard solution to each impactor stage/cup/
throat and to the standard used for API quantitation. In this
case, the sample solution is transferred directly to the LC vial
and the exact volume transferred is of no importance. The
exact concentration of the internal standard solution is not
critical as long as the internal standard dispenser is repeatable
and the same dispenser is used for both samples and standard
solutions.
Stress and Fatigue
In complex operations, such as CI measurements, stress
and fatigue always deteriorate human performance, leading
to increased incidence of errors (7). These adverse influences
can be minimized by limiting the number of samples to be
analyzed per day.
Certain mechanical aids and procedural steps could be
introduced to counteract potential operator-related errors.
For example, to prevent delivery of an incorrect number of
doses to the impactor, use of “counters” linked to activation
of the airflow valve may be considered for DPIs; or, the
weighing of MDIs could be used before and after the CI test
to verify the correct number of doses actuated. As another
example, to enable detection of a mix-up of vials from
different stages during HPLC analysis, for uni-modal and
log-normal APSD distributions, plotting log-probability vs
log-particle-size and calculating the regression coefficient
could be used as a system suitability tool. Furthermore,
mixed-up dilutions could be avoided by using the same
amount of solvent for each impactor stage; or by eliminating
the dilution step altogether if the detection sensitivity and
linearity allow.
Bias Introduced by Experienced Operator
Even well-trained experienced operators can develop
habits that lead to repetitive mistakes in technique. Such
errors can often be small but taken together they can
accumulate so that the rate of measurement failures increases
above typical. Biases from individual operators could be
detected through use of control charts (e.g., mass of API
reported on key stages tracked as a function of time), and
upon further investigation they might be traced to one of the
errors listed above. Control charts are particularly useful with
repeated testing of established products.
Machine (CI System)
An APSD measurement is never “absolute” but depends
on the technique (28–31), instrument calibration (1), its
intrinsic size resolution, as well as the dynamic nature of the
aerosol cloud as it interacts with the environment as it enters
and passes through the CI (e.g., evaporation kinetics,
hygroscopic growth). Therefore, the outcome of an APSD
measurement should always be reported along with the
specific instrument and technique used. As such, variations
of APSD across different techniques are not considered in this
article as part of method variability. However, even within the
same technique and same instrument type, there is variability
due to the factors which may vary with each physical specimen
of a given impactor type, and with the conditions at each
particular instance of measurement. Compared to other types
of analytical measurement, a CI does not have a reference
standard, such as a standardized polydisperse aerosol, with
which to validate the method, and in that sense every CI
measurement is unique. This makes CI data prone to bias and
increased variability. Even with the method optimized, unno-
ticed biases and variability may remain, making it difficult to
comply with an a priori specification which disregards data
from that particular impactor and method. Careful method
development work should try to identify and counteract all
major sources of imprecision and bias. Many sources of
impactor-related variability have been described in the
literature, as summarized below.
In this section, the category “impactor” includes all
associated equipment, e.g., the pump creating the airflow and
the connecting vacuum tubing. Environmental factors (tem-
perature, humidity) are also included here in as much as they
affect the impactor performance. (The effect of such factors on
the product is not considered here.) Some of the impactor
parameters affecting CI method variability could be “fixed”
within a given method (e.g., impactor design, dead volume,
pump) and are discussed towards the end of this section. Other
parameters may change with time and/or with each instance of
measurement (e.g., surface quality, jet dimensions, air leakage,
coating thickness) and are discussed first.
Jet Dimensions, Stage Cut-offs, Calibration and Mensuration
Translation of CI deposition data into a particle size
distribution depends on the stage “cut-off” sizes (effective
cut-off diameters (ECDs) (2,32). Stage ECDs are determined
principally by the actual sizes (diameters) of the nozzles for
each stage in a given impactor (33). Several studies have
shown, however, that stages of so-called identical CIs have
often slightly different nozzle sizes, due either to manufac-
turing variations or caused by wear, corrosion or accumula-
tion of debris. Partial plugging, wear and corrosion will
change the actual size of the nozzles and ECD. These effects
result in shifts of API mass between stages (34–36) and,
therefore, in bias and increased variability of APSD measure-
ments, especially when data from several impactors are used
together (34).
To determine actual ECDs for a given CI, impactor
calibration is undertaken with particle standards of known
size which is ultimately traceable to the international standard
of length (37). Calibration of impactors, however, is a highly
407 Minimizing Variability of Cascade Impaction Measurementslaborious and expensive process (2) and it is not practically
feasible to use it routinely to monitor the performance of an
impactor. Therefore, the application of stage mensuration as
recommended in the pharmacopeial methods (23) (using
optical imaging techniques to measure the diameter or area
occupied by each nozzle) as a means to assess effective stage
nozzle diameters, continues to be used and investigated as the
technique of choice for CI performance verification (32,38–
42). Errors in mensuration using stop-go pins have been
reported (43), although these pins could be useful for cleaning
impactor jets. Recently, the determination of pressure-drop
across each stage, which may be performed before every
APSD measurement, has been proposed as a surrogate for
stage mensuration (44).
Flowrate, Flow Profile, Acceleration and Control
Stage ECDs are also affected by the flowrate at which the
impactorisoperated(45). Relatively speaking, nozzle-diameter-
caused variability in ECD, which is discussed above, is likely to
be small in terms of its overall impact on performance, and
relatively easily monitored. Flowrate-induced variability, how-
ever, is likely to be more significant and less tractable, given the
fact that in the pharmacopeial method, the specified flow
control is typically no better than ±5% of the nominal flowrate
(23). An alternative to the pharmacopeial method, using a
flow-meter calibrated for the entering, rather than exiting,
flowrate has been shown to yield similar performance (46).
Flowrate variability is an important source of APSD measure-
ment uncertainty, and may vary from one instance of using an
impactor to the next instance of using the same impactor.
For MDIs, stage ECDs are determined by the magnitude
of the (constant) flowrate achieved during testing; for DPIs,
in addition, the flow profile (rise time, acceleration) affects
stage ECDs and consequently the measured APSD. The
magnitude and direction of these effects depend on the CI
design and internal geometry, e.g., the internal dead volume
(47–49). It is important to define the vacuum tube length for
repeated use of the same impactor type in order to keep the
dead volume as constant as possible. The airflow rise time
could also be measured as part of the installation checks of a
new instrument set-up. Flowrate bias can be minimized if
flow-meters are well-maintained, properly calibrated and
regularly qualified.
Dead Volume
In the context of DPI testing, the magnitude of the
internal dead volume (open space within the assembled CI,
including accessories such as the induction port or pre-
separator, and vacuum tubing) will influence both the time
taken for particles to traverse the system and be collected,
as well as the rise time for the flowrate to increase to the
final value when the flow control solenoid valve is opened
to initiate sampling (2). Recently, the dead volumes of the
ACI, NGI and multi-stage liquid impinger (MSLI) were
accurately measured with and without the various accessories
(50). This information provides a useful starting point when
selecting a CI for a new product. Bias introduced to APSD
measurements by dead volume will be fixed for a given
impactor type and configuration, and ideally the internal
volume should be as small as possible. However, the trade-
off between potential bias arising from dead volume and
other more important constraints, such as ease of (semi)
automation or improved aerodynamic size separating char-
acteristics may result in the choice of a system with a higher
internal volume.
Air Leakage
Air leakage into the CI can arise from incorrectly placed
or defective seals or misaligned stages. The problem is
particularly prevalent with the standard O-rings used with
ACIs, which are prone to cracking with repeated use and
exposure to solvents. Defective seals are most significant
when they occur at stages closest to the impactor exit, where
the pressure inside the stage is at its lowest with respect to the
surrounding atmosphere. Since the CI operates under suction
from its pump, any air leakage will be into the system. It
therefore follows that although the APSD may be shifted (in
some cases significantly), the magnitude of the displacement
being dependent on leak location and size, the mass balance
(MB) for the API will likely be unaffected. Additionally, an
increase in inter-stage deposition could occur, which could
affect MB if such deposition is not included in the analysis
(7). Air leaks are detected and prevented through periodic
inspection of seals, careful attention to system assembly, and
by comparing the flowrate at the impactor inlet with that
downstream of the system as a system suitability check.
However, even if these checks are made, it is possible for a
small leak between stages to go unnoticed. As part of the CI
method development, companies may want to study the
effect of leaks on their product’s APSD through designed
experiments, e.g., by introducing controlled leaks through
small cuts in O-rings, and observing the changes in APSD
resulted from such simulated failures. This information could
later be used for root-cause analysis when atypical APSD
profiles are observed, in combination with re-assessment of
the tested unit to confirm that the failure is not related to the
product.
Environmental Conditions, Temperature and Humidity
Environmental conditions may influence variability of
the aerosol as it is generated by the delivery device (and thus
contribute to product variability), but they also may influence
APSD during the process of measurement. The first type of
influence is not considered here because it is product-specific.
The second type could be categorized as CI (method)-related
variability. Relative humidity will influence triboelectric
effects discussed later, and together with temperature it will
also affect droplet growth and evaporation throughout the CI
train (51–55), especially for aqueous droplets such as those
produced by nebulizers (2). Temperature variations may
additionally influence volumetric flowrate and thus further
affect the CI measurement. Usually, temperature, and to
some extent humidity, are monitored and controlled to
minimize these effects. The extent of environmental influen-
ces and the needed controls depend on the product type
(API, carriers, propellants, co-solvents, etc.), as well as on the
CI system and its other operating conditions (e.g., the
flowrate may affect the rate of particle growth and evapora-
408 Bonam et al.tion, the CI temperature may affect heat transfer and droplet
evaporation).
Triboelectrification and Electrostatic Charge
Aerosolized particles are known to carry electrostatic
charge generated chiefly by triboelectric effects (contact
electrification) during aerosol formation from both DPIs
(56–61) and MDIs (62–68). Electrostatic charge acquired by
the CI components that are non-conducting or electrically
insulated, may influence particle collection behavior (69) and
may increase variability of the measured APSD and MB.
Depending on the product, exploratory studies may be
warranted to optimize the method.
Plate Coating, Coating Thickness and Type
Coating CI plates has been found to reduce particle
bounce and re-entrainment, and thus reduce bias and variabil-
ity of CI measurements (49,70–71). This effect is particularly
important for DPI formulations and may also occur with
some MDI products (72), although it may be unimportant for
nebulizers (73). The appropriate coating material and thick-
ness are product-dependant. It is unknown, however, whether
coating prolongs or shortens plate-life by either preventing or
causing corrosion. These effects may also be formulation- and
materials-dependant. To standardize coating, some automa-
tion or use of a tool that ensures a uniform depth of coating
across the collection surface could be considered.
Stage Loading and Number of Actuations
With formulations requiring multiple actuations for CI
testing and containing a high mass-loading of particulates, it is
important to consider potential accumulation of material on
CI stages to the point at which further incoming particles
bounce (74). Not only the amount of API mass depositing on
stages needs to be low enough to prevent collected particulate
becoming re-entrained in the airflow and transferred to stage
(s) further in the CI system, but also the weight of excipient
(carrier) per stage must be taken into account. In the extreme,
excessive actuations may result in stage overloading that
could affect the jet-to-plate distance. If the number of
actuations used per a single CI test is too large, an apparent
shift to finer particle sizes will be observed (72,74–76). Some
recent studies suggest that the type of formulation may also
play a role (77). These biases should be studied and
eliminated in method development, prior to any method
validation, by undertaking measurements with progressively
increased numbers of actuations.
Surface Properties
Different roughness of uncoated stage surfaces may
influence ballistic behavior of aerosol particles and measured
variability. This effect may depend on the formulation, age of
the impactor, and cleaning/drying conditions; however, there
are no published data in which the effect of surface roughness
on APSD has been investigated. ACI vendors and US
Pharmacopeia now describe tolerances for surface roughness
but not as a requirement.
Cleaning/Drying
Proper cleaning/drying of impactor surfaces keeps them
as close to their specifications as possible. Variations in the
cleaning/drying procedures may affect variability of ASPD
measurements. This is obvious from the standpoint of
minimizing corrosion (long-term) and having unobstructed
jets prior to each measurement (short-term), although there
are no published data systematically studying the effect of
cleaning/drying regimen on APSD results. Appropriate
cleaning/drying procedures should be determined during
method development.
Internal (Wall) Losses
Internal losses of API to the non-collection surfaces
within a CI (wall losses) may be an important source of
error because of the non-linear association between their
magnitude and particle aerodynamic size. Calibration data
for the ACI, in which such losses were investigated
systematically, indicate a strong association between internal
losses and particle aerodynamic size, with increased non-
ideal deposition particularly evident with particles >5 μm
aerodynamic diameter (78). Losses in the pre-separator
supplied with this impactor were especially significant. Wall
losses should be determined during method development,
and be <5% of delivered mass; otherwise the material from
the entire stage including jets and walls (and not only the
impaction plate) should be collected and added to the total
dose recovered from the CI (23). Wall losses may depend on
the product and method (e.g., coating type, number of
actuations).
Induction Port
Theinductionport(IP)isimportantforMDItestingdueto
the need to capture the ballistic component separately from the
fraction that is intended to penetrate beyond the oropharynx
into the lower respiratory tract (79). The IP presents the first
impaction surface for the moving aerosol once it has left the
inhaler (and any add-on device), and therefore, it strongly
affects the proportion of the emitted mass entering the
impactor. For this reason, the use of adapters to align the
MDI actuator with the IP are important for ensuring correct
angle of entry of plume. With MDIs, the aerosol plume moves
faster than airflow in an IP, resulting in limited time for
evaporation and for the reduction in emitted droplet sizes.
Furthermore, for any given design of IP, deviations from
nominal dimensions and associated tolerances will influence
APSD measurements (80–83). Consideration should also be
given to the IP surface roughness as this may influence the
variability. For nebulizers, an IP is unnecessary because of the
absence of the ballistic fraction in nebulizer-produced aerosols.
Pump
Different pumps may produce different time-dependent
flowrate profiles, which are important for DPI testing. The
pump-capacity-relatedvariabilityisminimizedbyoperating the
impactorwith the flow set bymeans of a criticalorifice (23)a n d
by measuring the critical flow (P3/P2<0.5, where P2 and P3
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valve) (23,84). Because pumps heat up and lose efficiency
over time if left running, flowrate setting/verification and
APSD measurement should be conducted as quickly as
possible.
Impactor Design
The design of an impactor is another fixed contributor to
the overall method variability. The ideal impactor will have
stage collection efficiency-versus-particle size curves that are
each a step function at the ECD for that stage (2). In practice,
this ideal is never achieved, and the collection-efficiency
curves of real impactors are sigmoidal in shape, often with
slight asymmetry that is associated with non-inertial behavior
(i.e., ultra-Stokesian drag and gravitational settling) (85–86).
The square root of the ratio of the sizes that correspond to
the 84.1st and 15.9th percentiles of these curves has been
defined as a quantitative measure of size discrimination, by
analogy with the definition of geometric standard deviation as
the measure of spread of a cumulative size distribution
function. In a well-designed impactor such as the NGI, this
value should be close to or <1.2 (1.0 represents the ideal step
function) (87–88). As well as affecting its size-discriminating
capability, the CI design influences the internal airflow
characteristics and, therefore, the magnitude of non-ideal
deposition on internal surfaces, and in turn, therefore the
variability and bias of CI results.
Measurement (Analysis)
To assay API deposited on CI stages, HPLC/spectropho-
tometry may be employed, which is a well-characterized and
easily standardized technique. Nevertheless, this is yet
another area contributing to both random and systematic
uncertainty of CI measurements, leading to reduced precision
and accuracy of CI results. For example, one of the difficulties
of using assay as part of CI testing may be poor chromophore
properties of the API and/or low amounts of the API to be
assayed, often near the limit of detection (LOD) or limit of
quantitation (LOQ) of a given method. Another difficulty is
the high number of dilutions and wide ranges of concen-
trations (e.g., from LOQ for the lowest strength tested to
150% of the highest deposition for the highest strength
tested) necessary for a single CI experiment. The number of
actuations used per determination might need to be adjusted
to enable an accurate and precise detection method. Addi-
tionally, there may be product-specific complications contrib-
uting to the overall method variability, for example use of
highly volatile solvents (which may be necessary for certain
APIs), leading to erratic results due to solvent evaporation
during pipetting. Careful method development, involving
iterative evaluation and optimization, may help minimize
variabilities due to analysis.
Material (Product)
The APSD of the aerosol delivered by an inhaler or
nebulizer may have an inherent variability truly attributable
to the product, and there are a number of factors potentially
influencing this true APSD variability [e.g., product orienta-
tion during storage, formulation interaction with excipients,
interaction with components of container closer system,
sensitivity to moisture, product age, temperature and humid-
ity during storage, tolerances of device components, static
electricity effects during de-aggregation of some DPI for-
mulations, static electricity due to interaction of MDI aerosols
with non-conducting elastomers used in MDI valve manufac-
ture, (89–91), etc.]. All such factors should be studied during
product development and are not considered here in detail
because they are specific to the product rather than the CI
method, which is the focus of this review.
In addition, however, certain product characteristics may
make the method more variable. For example, suspensions
may by nature produce more variable aerosols than homoge-
neous solutions, arising from the intrinsic tendency for particle
segregation in suspensions (product variability). In addition,
for suspensions, the timing between shaking and actuation
(which is part of the “method”) may influence the measured
APSD variability. Similarly, for propellant-based MDIs, the
rate of actuation (part of the “method”) and accompanying
drop in the MDI temperature may affect the measured APSD
and consequently its variability.
Products combining more than one API may present
special challenges for developing a precise and accurate CI
method. For example, one of the APIs could be a strong
chromophore and the other a weak one, or one of the APIs
might reach the limit for stage loading and the other be at the
LOD level within the same number of actuations, or one could
be a hydrophilic compound and the other a hydrophobic one.
Furthermore, components of variability may arise due to
interactions (interdependences) between factors (Material,
Man, Machine, and Analysis), e.g., incorrect device cleaning
may induce particle growth, giving rise to a man–material
interaction component of variability.
Specifically designed experiments could be conducted to
separate variability components. The total mass collected
from a CI (mass balance) may be used more routinely as a
diagnostic tool to distinguish between a method-related and
product-related abnormality when deviating APSD results
are observed (7,92).
Interrelationships between Factors
The Ishikawa diagram is a useful tool in visualization of
potential root-causes of APSD variability (Fig. 1). However,
as already mentioned above, there may be many interactions
between the factors, whereby the influence of one factor
depends on the presence and magnitude of another or several
other factors. For example, from general physico-chemical
principles one can expect that the effect of static electricity on
the CI measurement could be stronger or weaker depending
on the air humidity, type of formulation and CI construction
materials. There could also be less obvious interactions
present (e.g., factors related to the specific handling tech-
nique of the CI operator, depending on the ambient
temperature or day or season). Interaction effects cannot be
easily depicted in an Ishikawa diagram but they should be
studied using designed experiments so that the CI method
could be optimized and appropriately controlled.
From Fig. 1 one may also notice that some factors appear
more than once, i.e. they affect more than one category. For
410 Bonam et al.example, the number of actuations may conceivably affect the
APSD uncertainty through man (e.g., due to repetitive stress
or differences in delay times when firing multiple actuations),
as well as through Machine (e.g., due to stage overload and
particle bouncing), as well as through measurement (e.g., due
to the limit of detection when the number of actuations is
small), as well as through material (e.g., due to suspension
resettling time). Method developers should be aware of this
complexity when optimizing a given CI method or conducting
an investigation of deviating results.
Method Optimized: What Next?
Even with the best possible method, some variability in CI
results will remain, and specific experiments should be carried
outto identify andquantify the contribution of major factors of
interest. The present report is intended to aid in the
identification of the most important factors. As a next step, a
sponsor should consider designing and conducting an experi-
ment to quantify the contribution of major factors, by
consulting specialized literature on design of experiments
(93–100). Such careful method development work will
increase sponsor’s understanding of the method capability
and variability, which in turn could help establish appropriate
quality control programs and acceptance criteria.
CONCLUSIONS
In order to produce pharmaceutical products of high
quality with maximum efficiency in line with the modern
regulatory quality-by-design concepts, a sponsor must achieve
and demonstrate an understanding and optimal design of the
product, test methods, and manufacturing process. The
current review could guide sponsors’ efforts to optimize
capability and variability of the CI test method, which is
frequently employed for one of the key quality measures of
inhaled products. Judging from published literature, of the
four major categories of factors affecting CI measurements,
impactor-related factors have been studied the most. Much
less published information, especially quantitative data, exists
about operator-derived influences, as well as the contribution
of API assay methodology and product-related causes to the
outcome of a CI test; specifically designed experiments by
individual sponsors or collaborative groups could therefore
significantly help advance our knowledge in these areas.
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